NL301202I1 - Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline - Google Patents

Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline

Info

Publication number
NL301202I1
NL301202I1 NL301202C NL301202C NL301202I1 NL 301202 I1 NL301202 I1 NL 301202I1 NL 301202 C NL301202 C NL 301202C NL 301202 C NL301202 C NL 301202C NL 301202 I1 NL301202 I1 NL 301202I1
Authority
NL
Netherlands
Prior art keywords
linzagolix
choline
pharmaceutically acceptable
acceptable salt
salt
Prior art date
Application number
NL301202C
Other languages
English (en)
Other versions
NL301202I2 (nl
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of NL301202I1 publication Critical patent/NL301202I1/nl
Publication of NL301202I2 publication Critical patent/NL301202I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NL301202C 2005-10-19 2022-11-01 Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline NL301202I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005304395 2005-10-19
JP2006147019 2006-05-26
PCT/JP2006/320681 WO2007046392A1 (ja) 2005-10-19 2006-10-17 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途

Publications (2)

Publication Number Publication Date
NL301202I1 true NL301202I1 (nl) 2022-11-09
NL301202I2 NL301202I2 (nl) 2023-01-24

Family

ID=37962485

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301202C NL301202I2 (nl) 2005-10-19 2022-11-01 Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline

Country Status (21)

Country Link
US (1) US9040693B2 (nl)
EP (1) EP1939204B3 (nl)
JP (2) JP4955566B2 (nl)
KR (1) KR101384132B1 (nl)
AU (1) AU2006305271B2 (nl)
BR (1) BRPI0617436B8 (nl)
CA (1) CA2624492C (nl)
CY (1) CY1113898T1 (nl)
DK (1) DK1939204T6 (nl)
ES (1) ES2398917T7 (nl)
HK (1) HK1125110A1 (nl)
IL (1) IL190754A (nl)
NL (1) NL301202I2 (nl)
NO (1) NO343185B1 (nl)
NZ (1) NZ567300A (nl)
PL (1) PL1939204T6 (nl)
PT (1) PT1939204E (nl)
RU (1) RU2418803C2 (nl)
SI (1) SI1939204T1 (nl)
TW (1) TWI400074B (nl)
WO (1) WO2007046392A1 (nl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124614A1 (en) * 2007-04-06 2008-10-16 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
BRPI0809931B8 (pt) * 2007-04-06 2021-05-25 Neurocrine Biosciences Inc antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo
JP5352449B2 (ja) * 2007-04-18 2013-11-27 キッセイ薬品工業株式会社 縮合へテロ環誘導体、それを含有する医薬組成物及びその医薬用途
CA2682400A1 (en) * 2007-04-18 2008-11-06 Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes
MX2012009323A (es) * 2010-02-10 2012-11-21 Kissei Pharmaceutical Sal de derivado heterociclico condensado y cristal del mismo.
CA2882879A1 (en) 2012-08-24 2014-02-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014042176A1 (ja) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
ES2713681T3 (es) * 2014-01-06 2019-05-23 Bristol Myers Squibb Co Moduladores de ROR gamma de sulfona carbocíclica
EA039240B1 (ru) * 2016-08-08 2021-12-22 Киссеи Фармасьютикал Ко., Лтд. ПРИМЕНЕНИЕ ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ 3-[2-ФТОР-5-(2,3-ДИФТОР-6-МЕТОКСИБЕНЗИЛОКСИ)-4-МЕТОКСИФЕНИЛ]-2,4-ДИОКСО-1,2,3,4-ТЕТРАГИДРОТИЕНО[3,4-d]ПИРИМИДИН-5-КАРБОНОВУЮ КИСЛОТУ ИЛИ ЕЁ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМУЮ СОЛЬ, В СПОСОБЕ ЛЕЧЕНИЯ ЭНДОМЕТРИОЗА
HUE058207T2 (hu) * 2017-01-31 2022-07-28 Veru Inc Készítmények és módszerek gonadotropin felszabadító hormon (GNRH) antagonisták elnyújtott idejû felszabadítására
CN110996956A (zh) 2017-06-05 2020-04-10 奥布赛瓦股份公司 用于治疗子宫内膜异位症的***释放激素拮抗剂给药方案
US11759464B2 (en) 2017-06-05 2023-09-19 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
CN112105608B (zh) * 2018-01-30 2023-07-14 因赛特公司 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
MA54058A (fr) 2018-10-29 2021-09-08 ObsEva SA Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale
MA54150A (fr) 2018-11-07 2021-09-15 ObsEva SA Compositions et méthodes de traitement de troubles dépendant des oestrogènes
CN114364384A (zh) * 2019-08-08 2022-04-15 奥布赛瓦股份公司 用于治疗***依赖性病症的GnRH拮抗剂
WO2021023877A2 (en) 2019-08-08 2021-02-11 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders
KR20230146640A (ko) * 2021-02-23 2023-10-19 소테르 바이오파마 피티이. 리미티드 융합된 폴리사이클릭 치환된 5-카복실산 티에노피리미딘 디온 화합물 및 이의 용도
CN116940575A (zh) * 2021-02-23 2023-10-24 深圳市康哲药业有限公司 噻吩并嘧啶二酮类化合物及其应用
TW202342054A (zh) 2022-02-04 2023-11-01 日商橘生藥品工業股份有限公司 經口固形製劑
WO2024037532A1 (zh) * 2022-08-16 2024-02-22 深圳市康哲生物科技有限公司 一种噻吩并嘧啶酮衍生物的盐型及晶型

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2192283A1 (en) 1995-12-08 1997-06-09 Nobuhiro Suzuki Prolactin production inhibitory agent
EP0906115A1 (en) * 1996-04-30 1999-04-07 Takeda Chemical Industries, Ltd. COMBINED USE OF GnRH AGONIST AND ANTAGONIST
EP0901489A1 (en) 1996-05-20 1999-03-17 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
CA2545725A1 (en) * 2003-11-14 2005-06-02 Merck Sharp & Dohme Limited Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
EP1697381A4 (en) 2003-12-19 2009-03-11 Merck & Co Inc INHIBITORS OF MITOTIC KINESINES
JPWO2006083005A1 (ja) * 2005-02-03 2008-06-26 武田薬品工業株式会社 縮合ピリミジン誘導体およびその用途

Also Published As

Publication number Publication date
HK1125110A1 (en) 2009-07-31
EP1939204A1 (en) 2008-07-02
NO20082249L (no) 2008-07-18
NL301202I2 (nl) 2023-01-24
PT1939204E (pt) 2013-03-14
TWI400074B (zh) 2013-07-01
ES2398917T7 (es) 2022-10-26
PL1939204T6 (pl) 2024-03-25
AU2006305271A1 (en) 2007-04-26
RU2008119462A (ru) 2009-11-27
NO343185B1 (no) 2018-11-26
CY1113898T1 (el) 2016-07-27
EP1939204B1 (en) 2013-01-02
ES2398917T3 (es) 2013-03-22
DK1939204T6 (da) 2022-09-05
PL1939204T3 (pl) 2013-06-28
US20090325900A1 (en) 2009-12-31
BRPI0617436B1 (pt) 2021-04-06
EP1939204B3 (en) 2022-08-24
CA2624492C (en) 2014-02-18
BRPI0617436B8 (pt) 2021-05-25
JP4955566B2 (ja) 2012-06-20
KR20080063827A (ko) 2008-07-07
SI1939204T1 (sl) 2013-05-31
TW200732309A (en) 2007-09-01
US9040693B2 (en) 2015-05-26
JPWO2007046392A1 (ja) 2009-04-23
AU2006305271B2 (en) 2011-11-17
JP5319797B2 (ja) 2013-10-16
IL190754A0 (en) 2008-11-03
JP2012102140A (ja) 2012-05-31
BRPI0617436A2 (pt) 2011-07-26
EP1939204A4 (en) 2010-09-01
CA2624492A1 (en) 2007-04-26
NZ567300A (en) 2010-11-26
KR101384132B1 (ko) 2014-04-10
WO2007046392A1 (ja) 2007-04-26
DK1939204T3 (da) 2013-03-11
IL190754A (en) 2012-10-31
RU2418803C2 (ru) 2011-05-20

Similar Documents

Publication Publication Date Title
NL301202I2 (nl) Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NL301106I1 (nl) Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL301256I2 (nl) cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301209I2 (nl) capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301003I2 (nl) Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan
NL300993I2 (nl) Apalutamide of een farmaceutisch aanvaardbaar zout daarvan
NL301150I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I2 (nl) crisaborole, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301166I2 (nl) Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NL301037I2 (nl) Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
NL301071I2 (nl) alpelisib of een farmaceutisch aanvaardbaar zout ervan
NL350108I2 (nl) Isofetamid of een zout daarvan
NL300886I2 (nl) baricitinib, of een farmaceutisch aanvaardbaar zout daarvan
FIC20240026I1 (fi) Etrasimodi tai sen farmaseuttisesti hyväksyttävä suola, kuten etrasimodiarginiini
NO2020034I1 (no) Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid
NL301261I2 (nl) Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL300865I2 (nl) Eluxadoline of een farmaceutisch aanvaardbaar zout ervan
NL301250I2 (nl) piflufolastat (18F) of een farmaceutisch aanvaardbaar zout daarvan
NL301042I1 (nl) Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
NL300990I2 (nl) Brigatinib, dan wel een farmaceutisch aanvaardbaar zout daarvan
NO2016016I2 (no) Lesinurad, eller et farmasøytisk akseptabelt salt derav
NO2018016I2 (no) Niraparib eller et farmasøytisk akseptabelt salt, stereoisomer eller tautomer derav
NL301021I2 (nl) talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.